This protocol targets metabolic dysfunction-associated steatohepatitis (MASH) in patients who also have type 2 diabetes mellitus — a comorbidity that directly influences which agents are appropriate and what additional metabolic burdens must be addressed simultaneously.
Type 2 diabetes mellitus co-occurring with MASH shapes the therapeutic priorities. Agent selection must account not only for hepatic disease but also for the full range of metabolic complications accompanying diabetes, including — when present — concomitant heart failure and chronic renal failure.
The regimen includes an insulin-sensitising agent with demonstrated histological improvement of steatohepatitis regardless of diabetes status, together with further agents chosen for the specific metabolic comorbidities this population carries.
Primary goal: improvement of steatohepatitis on histology.
DOI: 10.3350/cmh.2025.0045